SCHEMBL56203

SCHEMBL56203

COc1ccc(OC(=O)O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.60
CA2 P00918 5/20 0.60
CES2 O00748 2/20 0.56
CES1 P23141 2/20 0.56
CA12 O43570 1/20 0.55
CA7 P43166 1/20 0.55
CA9 Q16790 1/20 0.55
CA14 Q9ULX7 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
ALDH1A1 P00352 1/20 0.55
GAA P10253 1/20 0.55
HTT P42858 1/20 0.55
PARP1 P09874 1/20 0.52
PARP10 Q53GL7 1/20 0.52
PARP2 Q9UGN5 1/20 0.52
PARP4 Q9UKK3 1/20 0.52
LMNA P02545 2/20 0.52
RAB9A P51151 2/20 0.52
MEN1 O00255 1/20 0.52
MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11840046 0.98 CA1 (0.58) CA1CA2CES2CES1CA12
SCHEMBL8991731 0.95 GAA (0.56) CA1CA2CES2CES1CA12
SCHEMBL6223461 0.93 ESR2 (0.56) CA1CA2CES2CES1CA12
Guanidine SCHEMBL7470320 0.89 CA1 (0.53) CA1CA2CES2CES1SMN1; SMN2
SCHEMBL18363037 0.88 LMNA (0.66) CA1CA2CES2CES1SMN1; SMN2
SCHEMBL1690741 0.88 LMNA (0.66) CA1CA2CES2CES1SMN1; SMN2
SCHEMBL465132 0.87 LMNA (0.52) SMN1; SMN2ALDH1A1GAAHTTLMNA
SCHEMBL17248001 0.86 MAPT (0.49) CA1CA2CES2CES1SMN1; SMN2
Acetic Acid SCHEMBL1868800 0.86 LMNA (0.61) CA1CA2CES2CES1CA12
SCHEMBL1871227 0.85 LMNA (0.67) CA1CA2CES2CES1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114316096-A Functionalized polyolefin elastomer and preparation method thereof 常州汉韦聚合物有限公司 2022-04-12 CN claimed
EP-2154138-B1 NOVEL COMPOUNDS FOR TREATMENT OF PSYCHOTIC DISORDERS, PREPARATION METHODS AND USES THEREOF LI YOUXIN (CN) 2015-08-19 EP claimed
CN-118591539-A Substituted thiazolidinedione derivative compounds and pharmaceutical composition for preventing or treating cancer comprising the same (株)美迪菲 2024-09-03 CN disclosed
CN-118202006-A Resin composition, cured product, optical member, ultraviolet absorber, compound, method for producing compound, and polymer 富士胶片株式会社 2024-06-14 CN disclosed
CN-118176445-A Light absorbing filter, light filter, method for manufacturing light absorbing filter, organic electroluminescent display device, inorganic electroluminescent display device, and liquid crystal display device 富士胶片株式会社 2024-06-11 CN disclosed
US-11993697-B2 Flexible tube for endoscope, endoscopic medical device, and resin composition for covering flexible tube substrate for endoscope FUJIFILM CORPORATION (JP) 2024-05-28 US disclosed
US-20240150359-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2024-05-09 US disclosed
WO-2024085171-A1 LIGHT ABSORPTION FILTER, OPTICAL FILTER AND METHOD FOR PRODUCING SAME, ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE, INORGANIC ELECTROLUMINESCENT DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE 富士フイルム株式会社 2024-04-25 WO disclosed
WO-2024085172-A1 LIGHT ABSORPTION FILTER, OPTICAL FILTER AND METHOD FOR PRODUCING SAME, ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE, INORGANIC ELECTROLUMINESCENT DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE 富士フイルム株式会社 2024-04-25 WO disclosed
US-11958959-B2 Lens for spectacles and spectacles FUJIFILM CORPORATION (JP) 2024-04-16 US disclosed
WO-2024062843-A1 COLORED COMPOSITION, COLORED PRODUCT, AND COMPOUND 富士フイルム株式会社 2024-03-28 WO disclosed
EP-0180188-B1 A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-04-15 EP disclosed
US-4983609-A Anticancer agents OTSUKA PHARMACEUTICAL (JP) 1991-01-08 US disclosed
US-4914206-A ANTIBIOTICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1990-04-03 US disclosed
US-4864021-A ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-09-05 US disclosed
EP-0323441-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-07-05 EP disclosed
EP-0226896-A2 Lankacidin derivatives and production thereof Takeda Chemical Industries, Ltd. (JP) 1987-07-01 EP disclosed
EP-0180188-A2 A composition for increasing the anti-cancer activity of an anti-cancer compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-07 EP disclosed
US-4182726-A FROM THE PHENOL OR ESTER OF THE PHENOL SNAMPROGETTI, S.P.A. (IT) 1980-01-08 US disclosed
US-3989710-A POSTEMERGENCE HERBICIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150359-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS HAVCR2, EIF2AK2, OAT CA1 1982/4885CA2 1878/4885CES2 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.